X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dr. Reddys with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs MYLAN (US) - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DR. REDDYS LAB   MYLAN
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
MYLAN
Dec-14
DR. REDDYS LAB/
MYLAN
5-Yr Chart
Click to enlarge
High Rs2,7884,104-   
Low Rs1,9022,892-   
Sales per share (Unadj.) Rs860.81,405.0-  
Earnings per share (Unadj.) Rs57.1169.3-  
Cash flow per share (Unadj.) Rs122.0272.4-  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs757.7698.4-  
Shares outstanding (eoy) m165.91378.37-   
Bonus/Rights/Conversions ESOPOI-  
Price / Sales ratio x2.72.5 109.4%   
Avg P/E ratio x41.120.7 198.8%  
P/CF ratio (eoy) x19.212.8 149.7%  
Price / Book Value ratio x3.15.0 61.8%  
Dividend payout %35.00-   
Avg Mkt Cap Rs m389,0341,323,571 29.4%   
No. of employees `00023.525.0 94.1%   
Total wages/salary Rs m32,1490-   
Avg. sales/employee Rs Th6,070.821,264.0 28.5%   
Avg. wages/employee Rs Th1,366.60-   
Avg. net profit/employee Rs Th402.52,561.6 15.7%   
INCOME DATA
Net Sales Rs m142,810531,599 26.9%  
Other income Rs m1,552-3,099 -50.1%   
Total revenues Rs m144,362528,501 27.3%   
Gross profit Rs m23,512132,211 17.8%  
Depreciation Rs m10,77239,044 27.6%   
Interest Rs m78822,930 3.4%   
Profit before tax Rs m13,50467,139 20.1%   
Minority Interest Rs m0-275 0.0%   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,3802,823 155.1%   
Profit after tax Rs m9,46864,040 14.8%  
Gross profit margin %16.524.9 66.2%  
Effective tax rate %32.44.2 771.3%   
Net profit margin %6.612.0 55.0%  
BALANCE SHEET DATA
Current assets Rs m104,984467,346 22.5%   
Current liabilities Rs m68,938365,371 18.9%   
Net working cap to sales %25.219.2 131.6%  
Current ratio x1.51.3 119.1%  
Inventory Days Days7478 95.2%  
Debtors Days Days104107 96.6%  
Net fixed assets Rs m104,385122,984 84.9%   
Share capital Rs m83018,799 4.4%   
"Free" reserves Rs m124,8860-   
Net worth Rs m125,716264,257 47.6%   
Long term debt Rs m25,089394,774 6.4%   
Total assets Rs m225,4431,064,403 21.2%  
Interest coverage x18.13.9 461.7%   
Debt to equity ratio x0.21.5 13.4%  
Sales to assets ratio x0.60.5 126.8%   
Return on assets %4.58.2 55.7%  
Return on equity %7.524.2 31.1%  
Return on capital %9.713.6 71.2%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m53,7070-   
CASH FLOW
From Operations Rs m18,03069,879 25.8%  
From Investments Rs m-14,883-55,109 27.0%  
From Financial Activity Rs m-4,440-18,413 24.1%  
Net Cashflow Rs m-1,236-3,643 33.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 68.86 Rs / USD

Compare DR. REDDYS LAB With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare DR. REDDYS LAB With: LUPIN  FDC LTD.  CADILA HEALTHCARE  IPCA LABS  PANACEA BIOTECH  



Today's Market

Sensex Ends 222 Points Lower; Energy and Telecom Stocks Witness Selling(Closing)

Indian share markets witnessed most of the selling pressure during closing hours and ended their trading session lower.

Related Views On News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)

Mar 19, 2019

The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.

This Small Cap Stock Could Offer Triple Digit Gains from its Current Price(Profit Hunter)

Mar 19, 2019

If you are still waiting for signals, remember, there is no correct timing, only right time to Buy stocks. For select small caps, that time is now.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Mar 22, 2019 03:35 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS